Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519043 | 0.86 | HSP90AA1 (0.34) | TGFBR1 | |
| SCHEMBL3740474 | 0.85 | GPR119 (0.44) | FAAHGPR119BACE1TGFBR1KDM4E | |
| SCHEMBL3116823 | 0.81 | HSP90AA1 (0.38) | TGFBR1 | |
| SCHEMBL3116808 | 0.81 | HSP90AA1 (0.38) | TGFBR1 | |
| SCHEMBL13519786 | 0.81 | HSP90AA1 (0.51) | — | |
| SCHEMBL3748336 | 0.81 | HSP90AA1 (0.48) | — | |
| SCHEMBL13519774 | 0.78 | STS (0.44) | GPR119BACE1TGFBR1 | |
| SCHEMBL13519905 | 0.78 | HSP90AA1 (0.49) | — | |
| SCHEMBL13519866 | 0.78 | HSP90AA1 (0.49) | — | |
| SCHEMBL13519857 | 0.78 | HSP90AA1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | FAAH 3886/4885GPR119 672/4885BACE1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.